Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by TD Asset Management Inc.
TD Asset Management Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,224 shares of the biopharmaceutical company’s stock after selling 11,989 shares during the period. TD Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $25,649,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Highbridge Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $323,000. Raymond James Trust N.A. boosted its position in shares of Regeneron Pharmaceuticals by 9.2% in the first quarter. Raymond James Trust N.A. now owns 828 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 70 shares during the last quarter. National Pension Service boosted its position in shares of Regeneron Pharmaceuticals by 6.1% in the first quarter. National Pension Service now owns 60,037 shares of the biopharmaceutical company’s stock worth $23,185,000 after buying an additional 3,430 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Regeneron Pharmaceuticals by 55.0% in the first quarter. Bank of Montreal Can now owns 50,819 shares of the biopharmaceutical company’s stock worth $19,693,000 after buying an additional 18,030 shares during the last quarter. Finally, Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares during the last quarter. 66.70% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals, Inc. (REGN) opened at 466.59 on Friday. The firm has a market capitalization of $49.47 billion, a price-to-earnings ratio of 46.81 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The company has a 50 day moving average price of $495.54 and a 200 day moving average price of $426.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.82 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current fiscal year.
REGN has been the subject of a number of analyst reports. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a research report on Tuesday. Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price objective for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $489.35.
In related news, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the transaction, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. Insiders sold 56,922 shares of company stock valued at $27,383,105 in the last three months. Insiders own 10.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.